Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.
Study ties Ozempic-like drugs to dozens of benefits and risks
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to increase the risk of many others.
Ozempic and Wegovy: Scientists Uncover New Risks of Popular Weight-Loss “Miracle Drugs”
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,
Ozempic can help other chronic health conditions: Study | Morning in America
According to a Nature Medicine study, weight loss drugs can be highly effective in improving several unexpected health conditions. Dr. Anthony Harris discusses why he believes the FDA should update the drug's label to include other conditions it can treat.
Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises
A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — and even some new potential upsides. Analyzing the medical records of roughly 2.
Ozempic can lower chances of multiple health conditions but comes with risks, study finds
Ozempic, Wegovy, Zepbound and other drugs often used for weight loss can help lower the risk of a wide range of health conditions, according to a new study. But the drugs also pose certain risks. Kyle Benning explains.
A New Study Explored the Pros and Cons of Drugs Like Ozempic
GLP-1 drugs like Ozempic and Wegovy were initially used — and still are used — to treat diabetes. But in recent years, the uses of this class of drugs have grown in number. Nowadays, Ozempic and its ilk are often used for weight loss — and have shown promise in addressing other health issues.
Novo Nordisk stock surges 12% as an Ozempic alternative shows promising weight loss
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...
India Today on MSN10d
How Ozempic, Zepbound, and Mounjaro will transform India's weight loss market
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...
phillyvoice.com1d
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
decrypt2d
Landmark Study Reveals New Benefits and Risks of Obesity Drugs Like Ozempic
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Parade on MSN1d
Oprah Winfrey Admits Her Opinion of ‘Thin People’ Changed After Using Drugs Like Ozempic
Oprah Winfrey is opening up about how using weight-loss drugs (like Ozempic, Wegovy and Mounjaro) has impacted the way she ...